All In Biotech

NDA 211939 · Alvogen

Bonsity

Teriparatide · Subcutaneous · Parathyroid Hormone Analog

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 4, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

155

34 Phase 3, 5 recruiting

FAERS reports

7,181

4,999 serious, 411 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. Teriparatide injection is a parathyroid hormone analog, (PTH 1-34), indicated for: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 ) Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy ( 1 )

Mechanism: Endogenous 84-amino acid parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney. Physiological actions of PTH include regulation of bone metabolism, renal tubular reabsorption of calcium and phosphate, and intestinal calcium absorption. The biological actions of PTH and teriparatide are mediated through binding to specific high-affinity cell-surface receptors. Teriparatide and the 34 N-terminal amino acids of PTH bind to these receptors with the same affinity and have the same physiological actions on bone and kidney. Teriparatide is not...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 16, 2023 Supplement 4 · Efficacy LabelLetter
  • Oct 4, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • BONSITY · TERIPARATIDE 0.56MG/2.24ML (0.25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Teriparatide" as an intervention, any sponsor and status, largest first.

All 155 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness527
  • nausea525
  • fall505
  • fatigue487
  • back pain474
  • arthralgia462
  • device malfunction452
  • product dose omission issue436
  • pain in extremity425
  • pain398
  • headache391
  • device operational issue361

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
200533
200616
200757
200840
200952
201044
201185
2012307
2013509
2014150
2015142
2016129
2017310
2018437
2019492
2020228
2021185
2022299
2023476
2024986
20251,382
2026812

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 489 on PubMed

Sponsor: Alvogen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.